Dr. Dino Prato discusses custom-building immunotherapy, highlighting its limitations and potential for patients with stage four melanoma.

He explains that treatments like Keytruda only work long-term for a small percentage of patients and that many are not candidates due to "cold" tumors, an important aspect of modern oncology. Dr. Dino Prato explores how advancements in immunotherapy for cancer are shaping the future of cancer treatment, emphasizing the role of the immune system in fighting the disease.

🎯 What You’ll Learn in This Episode

• Why immunotherapy doesn’t work for all patients
• What checkpoint inhibitors actually do
• The role of immune signaling in cancer response
• Why tumor biology differs between patients
• What “cold tumors” mean
• How tumor microenvironment affects treatment
• Why deeper testing is being explored
• How personalized approaches may guide care

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Immunotherapy isn’t one-size-fits-all — it depends on how your immune system and tumor interact.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493